Keytruda's reign continues; pharma's megadeal drought [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
This story was originally published on PharmaVoice . To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter Some of the biggest news and trends captured in PharmaVoice's newsletter this week. Sign up here to receive the newsletter daily. Keytruda reigns supreme GLP-1s have quickly become a pharma sensation — but neither of the industry's blockbuster weight loss drugs knocked Keytruda from its top sales perch in 2025. Merck & Co.'s behemoth cancer checkpoint inhibitor raked in over $35 billion last year, retaining its position as pharma's best-selling drug. Eli Lilly's Mounjaro claimed the No. 2 spot with $23 billion in sales while Novo Nordisk's Ozempic was close behind at over $20 billion. Keytruda's dominance isn't likely to last as it approaches a patent cliff and weight loss drugs continue their climb. But the landmark therapy will have long legs in oncology, especially as a combo treatment. This week, we zoomed in on its stellar result
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- ????????????????: 2036????????? [CNET News]CNET News
- Merck's WELIREG Kidney Cancer Trials Deepen Oncology Growth Story [Yahoo! Finance]Yahoo! Finance
- Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150 [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (MRK) had its price target raised by Wells Fargo & Company from $135.00 to $150.00. They now have an "overweight" rating on the stock.MarketBeat
- Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- MRK's page on the SEC website